NHLBI SBIR Phase IIB Bridge Awards to Accelerate the commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44)
|Incentive Type:||Grant Program|
Health And Safety, Technology
|Governing Body:||National Institutes of Health|
|What’s it worth?:||$3,000,000|
The NHLBI SBIR Phase IIB Bridge Awards to Accelerate the commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases program awards funds to accelerate the capital-intensive steps required to transition to Phase II projects. This funding opportunity gives preference to applications deemed likely to result in commercial products and benefit clinical practice by accelerating the commercialization of new products and technologies. All proposals must assist the NHLBI in achieving the mission.
$7,000,000 is available for allocation with grant. Applicants are encourage to contact the NIH program officials before proposing anything in excess of the guidelines.
Applications must be complete and received before the deadline.